Skip to main content
. 2012 Oct 25;1(1):65–70. doi: 10.3892/br.2012.28

Figure 6.

Figure 6.

Summary of findings. First, irbesartan activates PPARγ and then hepatocyte growth factor (HGF) is upregulated and exerts favorable effects against pathological characteristics of metabolic syndrome (MS). When this signaling is blocked, these beneficial effects are reduced. PPARγ; peroxisome proliferators activated receptor-γ.